Skip to main content
SpringerLink
Log in

Chemotherapy of Prostatic Cancer

  • Chapter
Adenocarcinoma of the Prostate

Part of the book series: Clinical Practice in Urology ((PRACTICE UROLOG))

Abstract

Optimal management of patients with hormone-refractory prostatic cancer remains problematic. While there is some acceptance of the results of numerous clinical studies which have reported that chemotherapy is superior to further hormonal approaches or other supportive measures as a treatment option for hormone-refractory prostatic cancer, there persists a “general pessimism” about the use of chemotherapy in this patient population (Scott et al. 1976; Murphy et al. 1977; Logathetis et al. 1983; Torti 1983). This pessimism may be caused in part by the variability in clinical course of metastatic prostatic cancer and the problems in determining response to therapy in a systemic stage of disease which is particularly difficult to quantify. Since there is reason to question the overall impact of hormonal therapy in advanced prostatic cancer, it is not surprising that the impact of chemotherapy, which may cause a far less dramatic response, is all the more controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Beynon LL, Chisholm GD (1984) The stable state is not an objective response in hormone—escaped carcinoma of prostate. Br J Urol 56: 702–705

    Article  PubMed  CAS  Google Scholar 

  • Bulbul M, Huben RP, Murphy GP (1986) Interferon-β treatment of metastatic prostate cancer. J Surg Oncol 33: 231–233

    Article  PubMed  CAS  Google Scholar 

  • Chisholm GD, Stone AR, Beynon LL, Merrick MV (1982) The bone scan as a tumor marker in prostatic carcinoma. Eur Urol 8: 257–260

    PubMed  CAS  Google Scholar 

  • Citrin DL, Hogan TF, Davis TE (1983) Chemohormonal therapy of metastatic prostate cancer. A pilot study. Cancer 52: 410–414

    Article  PubMed  CAS  Google Scholar 

  • Citrin DL, Elson P, DeWys WD (1984) Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease. Cancer 54: 13–17

    Article  PubMed  CAS  Google Scholar 

  • Creaven PJ (1984) Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancer. Prostate 5: 484–493

    Google Scholar 

  • Creaven PJ, Madajewicz S, Mittelman A (1984) New potential treatment modalities for disseminated prostatic cancer. Urol Clin North Am 11: 343–353

    PubMed  CAS  Google Scholar 

  • deKernion JB, Lindner A (1984) Chemotherapy of hormonally unresponsive prostatic carcinoma Urol Clin North Am 11: 319–326

    CAS  Google Scholar 

  • deVere White R, Babayan RK, Krikorian J, Krane RJ, Olsson CA (1983) Adjuvant chemotherapy for stage Dx adenocarcinoma of prostate. Urology 21: 270–272

    Article  PubMed  CAS  Google Scholar 

  • Droller MJ (1985) Immunotherapy in genitourinary neoplasia. J Urol 133: 1–5

    PubMed  CAS  Google Scholar 

  • Eisenkraft S, Huben RP, Pontes JE (1984) Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases. Urology [Suppl] 23: 51–53

    Article  CAS  Google Scholar 

  • Fitzpatrick JM, Constable AR, Sherwood T, Stephenson JJ, Chisholm GD, O’Donoghue EPN (1978) Serial bone scanning: the assessment of treatment response in carcinoma of the prostate. Br J Urol 50: 555–561

    Article  PubMed  CAS  Google Scholar 

  • Guinan P, Ray P, Shaw M (1984) Immunotherapy of prostate cancer: a review. Prostate 5: 221–230

    Article  PubMed  CAS  Google Scholar 

  • Herr WW (1982) Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexynitrosourea in the treatment of metastatic prostatic cancer. J Urol 127: 462–465

    PubMed  CAS  Google Scholar 

  • Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD (1980) Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression. Cancer 45: 1300–1310

    Article  PubMed  CAS  Google Scholar 

  • Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17

    Article  PubMed  CAS  Google Scholar 

  • Loening S, Narayana A (1980) Adjuvant chemotherapy to definitive treatment of prostate cancer. Prostate 1: 321–355

    Article  PubMed  CAS  Google Scholar 

  • Loening SA, Scott WW, deKernion J et al. (1981) A comparison of hydroxyurea, methyl- chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol 125: 812–816

    PubMed  CAS  Google Scholar 

  • Loening SA, Beckley S, Brady MF et al. (1983) Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 129: 1001–1006

    PubMed  CAS  Google Scholar 

  • Logothetis CJ, Samuels ML, vonEschenback AC, Trindale A, Ogden S, Grant C, Johnson DE (1983) Doxorubicin, mitomycin-C, and 5-fluorouracil ( DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1: 368–379

    PubMed  CAS  Google Scholar 

  • Murphy GP (1984) Chemotherapy: Is it effective in treatment of prostatic cancer? Urology [Suppl] 24: 41–47

    Article  CAS  Google Scholar 

  • Murphy GP (1979) Management of disseminated prostatic carcinoma. In: Murphy GP (ed) Prostate cancer. PSG, Littleton MA Sci Grp. 13: 213–233

    Google Scholar 

  • Murphy GP, Slack NH (1980) Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1: 375–382

    Article  PubMed  CAS  Google Scholar 

  • Murphy GP, Gibbons RP, Johnson DE et al. (1977) A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 118: 288–291

    PubMed  CAS  Google Scholar 

  • Murphy GP, Gibbons RP, Johnson DE et al. (1979) The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Am Assoc Genitourinary Surg 70: 69–71

    Google Scholar 

  • Murphy GP, Beckley S, Brady MF et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1272

    Article  PubMed  CAS  Google Scholar 

  • Page JP, Levi JA, Woods RL, Tattersall MN, Fox RM, Coates AS (1985) Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma. Cancer Treat Rep 69: 105–107

    PubMed  CAS  Google Scholar 

  • Penman DT, Holland JC, Bahna GF et al. (1984) Informed consent for investigational chemotherapy: patients’ and physicians’ perceptions. J Clin Oncol 2: 849–855

    PubMed  CAS  Google Scholar 

  • Scher H, Yagoda A, Watson RC, Serber M, Whitmore W (1984) Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131: 1099–1102

    PubMed  CAS  Google Scholar 

  • Schmidt JD (1093) Cytotoxic agents effective in prostate cancer. Semin Urol 1: 299–310

    Google Scholar 

  • Schmidt JD (1984) Cooperative clinical trials of the National Prostate Cancer Project: protocol 900. Prostate 5: 387–399

    Article  PubMed  CAS  Google Scholar 

  • Schmidt JD, Scott WW, Gibbons RP et al. (1979) Comparison of procarbazine, imidazole- carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121: 185–189

    PubMed  CAS  Google Scholar 

  • Schmidt JD, Scott WW, Gibbons R et al. (1980) Chemotherapy programs of the National Prostatic Cancer Project ( NPCP ). Cancer 45: 1937–1946

    PubMed  CAS  Google Scholar 

  • Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP (1976) The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116: 211–213

    PubMed  CAS  Google Scholar 

  • Servadio C, Mukamel E, Lurie H, Nissenkorn I (1983) Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology 21: 493–495

    Article  PubMed  CAS  Google Scholar 

  • Silverberg E (1986) Cancer statistics, 1986. CA 36: 9–25

    PubMed  CAS  Google Scholar 

  • Slack NH (1983) Results of chemotherapy protocols of the USA National Prostatic Cancer Project (NPCP). Clin Oncol 2: 441–459

    Google Scholar 

  • Slack NH, Murphy GP (1983) A decade of experience with chemotherapy of prostate cancer. Urology 22: 1–7

    Article  PubMed  CAS  Google Scholar 

  • Slack NH, Mittelman A, Brady MF, Murphy GP, Investigators in the National Prostatic Cancer Project (1980a) The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 46: 2393–2402

    Google Scholar 

  • Slack NH, Murphy GP, participants in the National Prostatic Cancer Project (1980b) Overview of chemotherapy programs of the NPCP. Prostate 1: 367–373

    Google Scholar 

  • Slack NH, Brady MF, Murphy GP, Investigators in the National Prostatic Cancer Project (1984) Stable versus partial response in advanced prostate cancer. Prostate 5: 401–415

    CAS  Google Scholar 

  • Soloway MS, deKernion JB, Gibbons RP et al. (1981) Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125: 664–667

    PubMed  CAS  Google Scholar 

  • Soloway MS, Beckley S, Brady MF et al. (1983) estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J Urol 129: 56–61

    Google Scholar 

  • Stephens RL, Vaughn C, Lane M et al. (1984) Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group Study. ICRDB Cancergram, Series CT16, No 84 /07, 5

    Google Scholar 

  • Straus MJ, Fleit JP, Engelking C (1982) Treatment of advanced prostate cancer with cyclophosphamide, doxorubicin, and methotrexate. Cancer Treat Rep 66: 1797–1802

    PubMed  CAS  Google Scholar 

  • Torti FM (1983) Prostatic cancer chemotherapy. Cancer Res 85: 58–69

    CAS  Google Scholar 

  • Torti FM, Carter SK (1980) The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 92: 681–689

    PubMed  CAS  Google Scholar 

  • Yagoda A (1983) Cytotoxic agents in prostate cancer: an enigma. Semin Urol 1: 311–322

    PubMed  CAS  Google Scholar 

  • Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cisdiamminedichloride platinum II. Cancer 44: 1553–1562

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. P. Huben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. P. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Urology, University of Toronto, Toronto General Hospital, Suite 14-205, The Eaton Wing, 200 Elizabeth Street, Toronto, Ontario, Canada, M5G 2C4

    Andrew W. Bruce FRCS, FRCS(C) (Professor and Chairman) (Professor and Chairman)

  2. Division of Urology, University of Toronto, Toronto General Hospital, Suite 14-209, The Eaton Wing, 200 Elizabeth Street, Toronto, Ontario, Canada, M5G 9Z9

    John Trachtenberg MD, FRCS(C) (Associate Professor, Career Scientist) (Associate Professor, Career Scientist)

  3. Ministry of Health, Province of Ontario, Canada

    John Trachtenberg MD, FRCS(C) (Associate Professor, Career Scientist) (Associate Professor, Career Scientist)

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Huben, R.P., Murphy, G.P. (1987). Chemotherapy of Prostatic Cancer. In: Bruce, A.W., Trachtenberg, J. (eds) Adenocarcinoma of the Prostate. Clinical Practice in Urology. Springer, London. https://doi.org/10.1007/978-1-4471-1398-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1398-0_12

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1400-0

  • Online ISBN: 978-1-4471-1398-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation